Because life depends on us™

Bio Supply Chain Academy (BSCA)

Supply Chain Management for Life Sciences

Oct 19-21, 2020

5th BSMA Europe
Annual Conference
La Hulpe (Brussels), Belgium
NOVEMBER 12, 2020

BSMA AWARDS PROMOTION INFORMATION

Archived Posts

Are supply chains ready in the life sciences and pharmaceuticals for “Made in the USA” or “Made in Europe” and the Inherent Challenges to Making the Adjustment
By Robbie Singh, MS, MBA In the wake of the Covid-19 pandemic, I and many others have witnessed our reliance on China and Asian countries for basic medical supplies (such as gowns, masks, gloves, and ventilators), leave aside many pharmaceuticals and active ingredients are made in China. This reliance on
Molecular Diagnostics Supply Chain and Breakthrough Therapies In Development: An Update!
      Reported by     Horacio Enriquez, Chairman, Suppliers Council, BSMA            Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  While the majority of cases result in mild symptoms, some progress to pneumonia and multi-organ
Mitigating US Dependence On China For Biopharmaceutical APIs & Drugs
  Devendra Mishra, Co-Founder and Executive Director, BSMA A widespread awakening from the current coronavirus epidemic is how vulnerable the bio-pharmaceutical supply chain of the US is on supply from China. As the spread of COVID-19 has witnessed shortages of PPE, masks and ventilators causing loss of human lives, the
WAR ON CORONAVIRUS PANDEMIC: SUPPLY CHAIN MANAGEMENT 360°
      Reported by     Horacio Enriquez, Chairman, Suppliers Council, BSMA   What is most important for Healthcare professionals in this crisis?  You see the images of these brave people on television, the Internet, and Online, and read about it daily. Protection of the healthcare professionals and first
OVERCOMING THE CORONAVIRUS PANDEMIC: A SUPPLY CHAIN MANAGEMENT IMPERATIVE!
Devendra Mishra Executive Director & Co-Founder BSMA The Coronavirus pandemic is the gravest “Black Swan” event experienced over a century.  Nassim Nicholas Taleb described it in his pioneering book, The Black Swan(1), as a large scale unpredictable and irregular event of massive consequence with an infinitesimally low probability of occurrence.
BSMA’s COMMITMENT TO COMMERCIALIZE CELL & GENE THERAPY
Devendra Mishra Executive Director, BSMA The innovative therapy of Cell and Gene Therapy has imposed Draconian demands on the supply chain of the embryonic industry in terms of production batch of one, sixteen day vein to vein lead time, cryogenic preservation and cold-chain logistics, chain of custody, real-time patient care
BSMA Member Company 4G Clinical Launches Innovative Clinical Supply Software Leveraging Natural Language Processing (NLP)
  Calabasas, January 21, 2020 – BSMA is pleased to recognize 4G Clinical, a member company, for introducing an innovative clinical supply optimization software to further optimize the drug development process. Powered by Natural Language Processing (NLP), the solution enables clinical supply professionals to continuously adapt to new trial information as protocol
The Need For Digital Networks To Support Cell And Gene Therapies
​By Carla Reed, president, New Creed LLC Cell and gene therapies are game changers. Critical health conditions that were once chronic or terminal are now being addressed, which is exciting news for patients and caregivers. But these therapies have a level of complexity from a supply chain perspective that needs new approaches,
“The 4 Pillars of a Successful Cell and Gene Therapy Launch”
Q&A with Kevin Cast & Paul Furgal of Archbow Consulting The 12th Annual Conference of BSMA in Burlingame, CA, on October 15, brought together over 170 executives discussing Commercialization of the embryonic industry of Cell and Gene Therapy. Subsequently, Devendra Mishra, Executive Director of BSMA had the opportunity to interview
“Digitalization Opportunities for Cell and Gene Therapy”
Q&A with Mandar Paralkar, Senior Director of SAP Systems The 12th Annual Conference of BSMA in Burlingame, CA, on October 15, brought together over 170 executives discussing Commercialization of the embryonic industry of Cell and Gene Therapy. Subsequently, Devendra Mishra, Executive Director of BSMA, had the opportunity to interview Mandar Paralkar, Senior